Kidney Effects of Empagliflozin in People with Type 1 Diabetes
Volume: 16, Issue: 11, Pages: 1715 - 1719
Published: Nov 1, 2021
Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower risk of cardiovascular and kidney events in people with type 2 diabetes. In the empagliflozin in type 1 diabetes clinical program (Empagliflozin as Adjunctive to inSulin thErapy [EASE]), glycemic control, body weight, and BP improved with empagliflozin as adjunct to insulin, although diabetic ketoacidosis risk was higher with the 10- and 25-mg doses versus the 2.5-mg dose. The kidney...
Paper Details
Title
Kidney Effects of Empagliflozin in People with Type 1 Diabetes
Published Date
Nov 1, 2021
Volume
16
Issue
11
Pages
1715 - 1719
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History